|
|
|
|
|
|
|
|
|
|
Glenmark Pharmaceuticals Ltd.
|
|
|
|
|
|
|
|
|
BSE Code |
532296
|
|
ISIN Demat |
INE935A01035
|
|
Book Value (Rs) |
650.55
|
|
|
NSE Code |
GLENMARK
|
|
Dividend Yield % |
0.25
|
|
Market Cap(Rs Mn) |
286703.17
|
|
|
TTM PE(x) |
68.90
|
|
TTM EPS(Rs) |
14.75
|
|
Face Value (Rs) |
1
|
|
|
|
|
|
|
|
|
Industry : Pharmaceuticals & Drugs |
House : Glenmark |
|
Incorporation Year
|
18-11 1977
|
|
Registered Office
|
B/2 Mahalaxmi Chambers,22 Bhulabhai Desai Road, , Mumbai,
Maharashtra-400026 .
|
|
ISINNO
|
INE935A01035
|
|
Phone
|
|
|
E-mail
|
complianceofficer@glenmarkpharma.com |
|
URL
|
www.glenmarkpharma.com |
|
Industry
|
Pharmaceuticals & Drugs
|
|
Chairman
|
Glenn Saldanha
|
|
Managing Director
|
Glenn Saldanha
|
|
Company Secretary
|
Harish Kuber
|
|
Listing
|
BSE,NSE,MCX
|
|
|
|
|